Pinalex
Pinalex Tab · Пиналекс · ocular peptide tablet
Pinalex is a commercial eye tablet that mixes ocular peptides with antioxidant cofactors (lutein, astaxanthin, and related label items). It is not Retinalamin, not Normoftal, and not a Cytomed Cytomax.
Mechanism of Action
No indexed Pinalex-specific human PK. Lutein/zeaxanthin eye literature is a different evidence body than Khavinson retinal peptides. Do not launder AREDS-style carotenoid data onto a peptide tablet, or Retinalamin parabulbar series onto Pinalex.
Pinalex is a commercial eye tablet that bundles ocular peptides with antioxidants (lutein, astaxanthin, and related cofactors on vendor labels). It is not a Cytomed Cytomax and not Retinalamin. Eye stacks name it; we map the Khavinson leaves to Visoluten / Normoftal / Retinalamin and treat Pinalex as an adjacent blend.
Source: Vendor labels; Khavinson ocular class PMID 15677927
Khavinson map
Adjacent (not padded into the 41)Used in bioregulator stacks
Manufacturer-style organ combinations - not FDA protocols. Every name is a live leaf.
The Khavinson school
Vladimir Khatskelevich Khavinson (1946–2024) spent five decades at what became the St. Petersburg Institute of Bioregulation and Gerontology arguing a simple, stubborn idea: aging is, in part, a failure of tissue-specific peptide signals, and those signals can be restored. The first products were not “peptides” in the Instagram sense. They were Cytamins - polypeptide fractions isolated from a named organ of young animals. Later commercial refinements of those fractions are sold as Cytomaxes (Cytomed / NPCRIZ): still mixtures, still oral capsules, still defined by the source organ rather than a single sequence. When the group identified short active motifs inside those mixtures, they synthesized them as Cytogens - di-, tri-, and tetrapeptides with a one-letter code (KE, AEDG, KED, EDR, KEDP, and so on).
That three-layer stack is the whole map. Cytamin / pharmaceutical extracts (Thymalin, Epithalamin, Cortexin, Retinalamin, Prostatilen) are the clinic-era injectables registered in the former Soviet pharmacopeia. Cytomaxes are the capsule complexes Cytomed still lists as a 21-SKU organ line. Cytogens are the defined synthetics. English-language educators, including Brenden Henry’s public writing at Peptide Science Institute, add a further commercial distinction - later analog SKUs (N-acetyl, amidate, “V2” complexes) sold as more stable or more diverse than the original Cytomed lots. That last layer is a product taxonomy, not a Khavinson paper. We describe it so readers are not gaslit by three bottles with the same organ name. We do not reproduce paid Peptide Mastery protocols, Precision Cell Method language, or anyone else’s course IP.
Full Cytamin → Cytomax → Cytogen map, literature limits, and how we counted 41
The mechanism Khavinson published is epigenetic, not receptor-agonist in the GLP-1 sense. Short peptides are claimed to enter nuclei, interact with DNA/histones, and reopen tissue-specific transcription that condensed with age (heterochromatin → euchromatin). Reviews in the Bulletin of Experimental Biology and Medicine and Neuroendocrinology Letters (PMID 14523363, 15677927, 23888677) are the citable core. Complementary GI pharmacology is not mystical: di- and tripeptides are PEPT1/LAT substrates, which is why oral capsules are even a conversation. What is not established in Western Phase 3 programs is organ-by-organ disease treatment, telomere reversal as a clinical endpoint, or the manufacturer claim that Cytomax is “a third stronger” than Cytogen. Those are NPCRIZ marketing sentences.
Khavinson’s group published hundreds of papers, many in Russian, many in the same journal family. That is a real literature. It is also a literature with limited independent Western replication, small n, and a habit of using one review PMID as a stamp on every organ. On this site a leaf earns its organ story, its Cytomax↔Cytogen pair, its sequence if it has one, and an honest sentence about what has not been shown. Reconstitution math belongs on cytogens sold as vials. Cytomax capsules do not get a fake 5 mg vial.
The 41 we treat as canonical are the 21 Cytomaxes on the public e-peptide/Cytomed list, the 12 Cytogens on that same commercial line (including Vesilut, which Western catalogs often drop), plus eight historically load-bearing molecules that sit beside the capsule SKUs: Epitalon, Vilon, Thymogen, Livagen, Cortagen, Prostamax, Thymalin, and Epithalamin. Honluten, Cortexin, Retinalamin, Prostatilen, Thymulin, N-acetyl-epitalon-amidate, Pinalex, and the GPL Man / GPL Femme kits are covered as adjacent - same school or same storefront, not padded into a fake 41.
Public English-language teaching (including Brenden Henry at peptidescienceinstitute.com) is cited as context, not copied. Paid Peptide Mastery / Peptide Salvation text stays theirs.
History of this molecule
English stack pages drop “Pinalex” into the vision protocol next to Visoluten. Vendor labels describe a tablet for visual fatigue and age-related acuity, often combining a peptide fraction with carotenoids.
That is a nutraceutical blend, not a Khavinson sequence paper. The Khavinson ocular map is three products: Visoluten (oral extract), Normoftal (cytogen), Retinalamin (injectable extract). Pinalex sits beside that map as a later SKU.
We add the leaf so /stacks/vision is not a dead end, then we send readers to the three actual Khavinson ocular identities.
Caveats
Not a glaucoma drug, not an AMD indication, not an eye drop. Carotenoid doses on a label do not make the peptide fraction evidence-based.
Full 41-map: Khavinson bioregulators index · Bioregulator stacks
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Vendor tablet | Per label | Oral | Not parabulbar Retinalamin. |
Administration
Expected Timeline
Who Is It For?
Catalog identity
LowNamed on vision stacks. Route to Visoluten / Normoftal / Retinalamin for the Khavinson line.
Safety & Considerations
Not a glaucoma or AMD drug. Carotenoid cofactors are a different evidence body than Khavinson retinal peptides.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Frequently Asked Questions
Is Pinalex Visoluten?▼
Why is it on the stacks hub?▼
References
- Khavinson VKh et al. “Tissue-specific effects of peptides.” Bulletin of Experimental Biology and Medicine (2005). PMID: 15677927
📚 Related Articles
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code